Literature DB >> 33791799

Selective serotonin reuptake inhibitor citalopram ameliorates cognitive decline and protects against amyloid beta-induced mitochondrial dynamics, biogenesis, autophagy, mitophagy and synaptic toxicities in a mouse model of Alzheimer's disease.

Arubala P Reddy1, Neha Sawant2, Hallie Morton2, Sudhir Kshirsagar2, Lloyd E Bunquin1,2, Xiangling Yin3, P Hemachandra Reddy2,4,5,6,7.   

Abstract

In the current study, we investigated the protective role of citalopram against cognitive decline, impaired mitochondrial dynamics, defective mitochondrial biogenesis, defective autophagy, mitophagy and synaptic dysfunction in APP transgenic mouse model of Alzheimer's disease (ad). We treated 12-month-old wild-type (WT) and age-matched transgenic APP mice with citalopram for 2 months. Using Morris Water Maze and rotarod tests, quantitative RT-PCR, immunoblotting, biochemical methods and transmission electron microscopy methods, we assessed cognitive behavior, RNA and protein levels of mitochondrial dynamics, biogenesis, autophagy, mitophagy, synaptic, ad-related and neurogenesis genes in wild-type and APP mice treated and untreated with citalopram. Citalopram-treated APP mice relative to citalopram-untreated APP mice exhibited improved cognitive behavior. Increased levels of mRNA associated with mitochondrial fission and ad-related genes; decreased levels of fusion, biogenesis, autophagy, mitophagy, synaptic and neurogenesis genes were found in APP mice relative to WT mice. However, APP mice treated with citalopram compared to citalopram-untreated APP mice revealed reduced levels of the mitochondrial fission and ad-related genes and increased fusion, biogenesis, autophagy, mitophagy, synaptic and neurogenesis genes. Our protein data agree with the mRNA levels. Transmission electron microscopy revealed significantly increased mitochondrial numbers and reduced mitochondrial length in APP mice; these were reversed in citalopram-treated APP mice. Further, Golgi-cox staining analysis revealed reduced dendritic spines in APP mice relative to WT mice. However, citalopram-treated APP mice showed significantly increased dendritic spines, indicating that citalopram enhances spine density, synaptic activity and improved cognitive function in APP mice. These findings suggest that citalopram reduces cognitive decline, Aβ levels and mitochondrial and synaptic toxicities and may have a strong protective role against mutant APP and Aβ-induced injuries in patients with depression, anxiety and ad.
© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33791799      PMCID: PMC8161521          DOI: 10.1093/hmg/ddab091

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  76 in total

Review 1.  Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeutics.

Authors:  P Hemachandra Reddy; Raghav Tripathi; Quang Troung; Karuna Tirumala; Tejaswini P Reddy; Vishwanath Anekonda; Ulziibat P Shirendeb; Marcus J Calkins; Arubala P Reddy; Peizhong Mao; Maria Manczak
Journal:  Biochim Biophys Acta       Date:  2011-10-19

Review 2.  Diabetic Neuropathy.

Authors:  Elina Zakin; Rory Abrams; David M Simpson
Journal:  Semin Neurol       Date:  2019-10-22       Impact factor: 3.420

3.  Alzheimer's disease.

Authors:  Gøril Rolfseng Grøntvedt; Tobias Navarro Schröder; Sigrid Botne Sando; Linda White; Geir Bråthen; Christian F Doeller
Journal:  Curr Biol       Date:  2018-06-04       Impact factor: 10.834

4.  Bioenergetic flux, mitochondrial mass and mitochondrial morphology dynamics in AD and MCI cybrid cell lines.

Authors:  Diana F Silva; J Eva Selfridge; Jianghua Lu; Lezi E; Nairita Roy; Lewis Hutfles; Jeffrey M Burns; Elias K Michaelis; ShiDu Yan; Sandra M Cardoso; Russell H Swerdlow
Journal:  Hum Mol Genet       Date:  2013-06-04       Impact factor: 6.150

Review 5.  Depression and risk of developing dementia.

Authors:  Amy L Byers; Kristine Yaffe
Journal:  Nat Rev Neurol       Date:  2011-05-03       Impact factor: 42.937

6.  Protective effects of reduced dynamin-related protein 1 against amyloid beta-induced mitochondrial dysfunction and synaptic damage in Alzheimer's disease.

Authors:  Maria Manczak; Ramesh Kandimalla; David Fry; Hiromi Sesaki; P Hemachandra Reddy
Journal:  Hum Mol Genet       Date:  2016-12-01       Impact factor: 6.150

7.  Fragmented mitochondria released from microglia trigger A1 astrocytic response and propagate inflammatory neurodegeneration.

Authors:  Amit U Joshi; Paras S Minhas; Shane A Liddelow; Bereketeab Haileselassie; Katrin I Andreasson; Gerald W Dorn; Daria Mochly-Rosen
Journal:  Nat Neurosci       Date:  2019-09-23       Impact factor: 24.884

Review 8.  Synaptic basis of Alzheimer's disease: Focus on synaptic amyloid beta, P-tau and mitochondria.

Authors:  Albin John; P Hemachandra Reddy
Journal:  Ageing Res Rev       Date:  2020-11-04       Impact factor: 10.895

9.  Protective effects of a natural product, curcumin, against amyloid β induced mitochondrial and synaptic toxicities in Alzheimer's disease.

Authors:  P Hemachandra Reddy; Maria Manczak; Xiangling Yin; Mary Catharine Grady; Andrew Mitchell; Ramesh Kandimalla; Chandra Sekhar Kuruva
Journal:  J Investig Med       Date:  2016-08-12       Impact factor: 2.895

View more
  6 in total

1.  Mitophagy enhancers against phosphorylated Tau-induced mitochondrial and synaptic toxicities in Alzheimer disease.

Authors:  Sudhir Kshirsagar; Neha Sawant; Hallie Morton; Arubala P Reddy; P Hemachandra Reddy
Journal:  Pharmacol Res       Date:  2021-11-08       Impact factor: 7.658

2.  Amyloid-β impairs mitochondrial dynamics and autophagy in Alzheimer's disease experimental models.

Authors:  Macarena de la Cueva; Desiree Antequera; Lara Ordoñez-Gutierrez; Francisco Wandosell; Antonio Camins; Eva Carro; Fernando Bartolome
Journal:  Sci Rep       Date:  2022-06-16       Impact factor: 4.996

3.  A partial reduction of Drp1 improves cognitive behavior and enhances mitophagy, autophagy and dendritic spines in a transgenic Tau mouse model of Alzheimer disease.

Authors:  Ramesh Kandimalla; Maria Manczak; Jangampalli Adi Pradeepkiran; Hallie Morton; P Hemachandra Reddy
Journal:  Hum Mol Genet       Date:  2022-06-04       Impact factor: 5.121

4.  Protective effects of mitophagy enhancers against amyloid beta-induced mitochondrial and synaptic toxicities in Alzheimer disease.

Authors:  Sudhir Kshirsagar; Neha Sawant; Hallie Morton; Arubala P Reddy; P Hemachandra Reddy
Journal:  Hum Mol Genet       Date:  2022-02-03       Impact factor: 5.121

5.  RALBP1 in Oxidative Stress and Mitochondrial Dysfunction in Alzheimer's Disease.

Authors:  Sanjay Awasthi; Ashly Hindle; Neha A Sawant; Mathew George; Murali Vijayan; Sudhir Kshirsagar; Hallie Morton; Lloyd E Bunquin; Philip T Palade; J Josh Lawrence; Hafiz Khan; Chhanda Bose; P Hemachandra Reddy; Sharda P Singh
Journal:  Cells       Date:  2021-11-10       Impact factor: 6.600

6.  A Combination Therapy of Urolithin A+EGCG Has Stronger Protective Effects than Single Drug Urolithin A in a Humanized Amyloid Beta Knockin Mice for Late-Onset Alzheimer's Disease.

Authors:  Sudhir Kshirsagar; Rainier Vladlen Alvir; Jangampalli Adi Pradeepkiran; Ashly Hindle; Murali Vijayan; Bhagavathi Ramasubramaniam; Subodh Kumar; Arubala P Reddy; P Hemachandra Reddy
Journal:  Cells       Date:  2022-08-27       Impact factor: 7.666

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.